P01.035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress

BACKGROUND: TMZ with short course radiotherapy (RT) is an option for elderly GBM patients. Nivolumab is a PD-1 inhibitor with known safety profile in GBM. An increase of mutations as we age is well documented in GBM and in cancer in general. A higher mutational load is associated with increased resp...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Khasraw, M, McDonald, K, Yip, S, Verhaak, R G, Heimberger, A B, Hall, M, Barnes, E, Hovey, E, Ellingson, B M, Lwin, Z
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Poster Presentations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144427/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.077
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky